Huahai Pharmaceutical’s Adalimumab Biosimilar Accepted by China’s CDE for Review
On December 14th, the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE)...
Insilico Medicine Receives $10 Million Milestone Payment for XL309 Clinical Progress
Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt...
Ascendis Pharma’s TransCon hGH sBLA for Adult GHD Accepted by FDA
Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) has announced that the US Food and Drug Administration...
Alibaba Health Reports 10.2% Revenue Growth and 72.8% Profit Increase in 2024 H1 Financials
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...
Novo Nordisk’s Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication
Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) has announced that the European Medicines Agency’s (EMA)...
Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
Germany-based pharmaceutical giant Bayer AG (ETR: BAYN) has announced the initiation of a Phase I...
CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255
Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China’s National Medical Products Administration...
Johnson & Johnson MedTech’s Impella Heart Pumps Gain FDA Approval for Pediatric Heart Failure
US major Johnson & Johnson MedTechhas announced receiving premarket approval (PMA) from the US Food...
Pfizer’s Ibrance Demonstrates Significant PFS Improvement in Phase III PATINA Trial
US pharmaceutical major Pfizer Inc. (NYSE: PFE) and Alliance Foundation Trials, LLC (AFT) have announced...
BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039
BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...
Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced that it has received approval from...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that its MET inhibitor, Orpathys (savolitinib),...
HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...
National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs
The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...
Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that it has received marketing...
HuidaGene Therapeutics Launches MUSCLE Study for CRISPR Therapy in Duchenne Muscular Dystrophy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced the initiation of the MUSCLE study for...
Sunshine Lake Pharma Files for HKEX IPO, Expanding Global Pharmaceutical Reach
China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to...
Transcenta’s LIV-1 ADCs Show Promising Results in Pre-Clinical Breast Cancer Study
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) announced updated results from a pre-clinical study...
Mabwell Bioscience Secures Licensing Deal with TABUK Pharmaceutical for MENA Region
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has inked a licensing deal with TABUK...
ImmunoTech Biopharm’s CAR-T-19 Earns Breakthrough Therapy Designation for B-ALL Treatment
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced receiving...